T-Cell Therapies for Epstein-Barr Virus–Associated Lymphomas

Abstract

Epstein-Barr virus (EBV)-associated lymphomas represent a broad spectrum of diseases and can be characterized by their pattern of viral latency. These pathologies display the importance of healthy T cell–mediated control of the EBV-infected B cells. Burkitt's lymphoma is the least immunogenic and has a type I latency pattern. Hodgkin's and a variety of non-Hodgkin's lymphomas exhibit antigens of type II latency. Posttransplant lymphoproliferative disease in the solid organ and hematopoietic stem cell transplant setting as well as lymphomas arising in primary immunodeficiency patients are tumors with type III latency. This last group expresses all 9 latent proteins and is the most immunogenic. T-cell approaches including donor lymphocyte infusions and the adoptive transfer of EBV-specific cytotoxic T lymphocytes can be used to treat these diseases. The authors describe the biology of these EBV-associated lymphomas and review the methodology and outcomes of existing T cell–based therapies as well as strategies to improve their efficacy.

Keywords :

• HSCT
• immunotherapy
• lymphoma
• lymphoproliferative disorders